Equillium, Inc. Stock News
$0.74
6.63%
today
Nasdaq,
Dec 30, 10:00 pm CET
Equillium, Inc. Stock News
Neutral
Business Wire
●
about 2 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. “At the end of October we announced that our ...
Neutral
Business Wire
●
2 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights...
Neutral
Business Wire
●
3 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The confere...
Neutral
Business Wire
●
6 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 m...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
